Anónimo. Evolocumab (Repatha) - A second PCSK9 inhibitor to lower LDL-cholesterol. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:140-1. [Ref.ID 99812]

Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology 2015;8:189-99. [Ref.ID 99700]

Burton BK, Balwani M, Feillet F, Varic I, Burrow TA, Grande CC, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Nightingale S, Peters H, Scarpa M, Schwab O, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med 2015;373:1010-20. [Ref.ID 99532]

Downs JR, O'Malley PG. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S.. Ann Intern Med 2015;163:291-7. [Ref.ID 99500]

Hovingh GK, Kastelein JJP, van Deventer SJH, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipadaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2. Lancet 2015;386:452-60. [Ref.ID 99483]

Goulooze SC, Cohen AF, Rissmann R. Lomitapide. Br J Clin Pharmacol 2015;80:179-81. [Ref.ID 99474]

Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E. PCSK9 inhibitors: a new era in lipid-lowering treatment?. Ann Intern Med 2015;163:64-5. [Ref.ID 99337]

Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry US, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino Sr RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ. Effect of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40-51. [Ref.ID 99336]

Takeuchi Y. Atypical antipsychotics and the risk of hyperlipidemia: A sequence symmetry analysis. Drug Saf 2015;38:641-50. [Ref.ID 99240]

Stone NJ, Lloyd-Jones DM. Lowering LDL cholesterol is good, but how and in whom?. N Engl J Med 2015;372:1564-5. [Ref.ID 99059]

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Med M, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. [Ref.ID 99056]

Anónimo. Lomitapide. Prescrire 2015;35:168-71. [Ref.ID 98923]

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (CC) . Eur Heart J 2015;36:1012-22. [Ref.ID 98806]

Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Scott R, Wasserman SM, Stein EA, for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. [Ref.ID 98743]

Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Wasserman SM, Gaudet D, for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. [Ref.ID 98742]

Miedema MD, López FL, Blaha MJ, Virani SS, Coresh J, Ballantyne CM, Folsom AR. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US cohort: the atherosclerosis risk in communities study cohort. JAMA Intern Med 2015;175:138-40. [Ref.ID 98727]

Gómez-Huelgas R, Martínez-Sellés M, Formiga F, Alemán Sánchez JJ, Camafort M, Galve E, Gil P, Lobos JM. Tratamiento de los factores de riesgo vascular en el paciente mayor de 80 años. Med Clin (Barc) 2014;143:134. [Ref.ID 97840]

González-Molero I, Rojo G, Morcillo S, Pérez-Valero V, Rubio-Martín E, Gutiérrez-Repiso C, Soriguer F. Relación entre déficit de vitamina D y síndrome metabólico. Med Clin (Barc) 2014;142:473-7. [Ref.ID 97741]

González-Parra E, Egido J. Vitamina D, síndrome metabólico y diabetes mellitus. Med Clin (Barc) 2014;142:493-6. [Ref.ID 97647]

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Slein EA, for the DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19. [Ref.ID 97589]